文献速递心脑血管急症重症综合管理与镇静镇痛

波形形态作为颅内压监测的替代指标:有创与无创方法的比较

Waveform Morphology as a Surrogate for ICP Monitoring: A Comparison Between an Invasive and a Noninvasive Method.
PubMed 文献 · Neurocrit Care · 2022-03-24
一句话结论在卒中患者中,无创ICP波形监测(Brain4care)的P2/P1比值与有创ICP一致性较强(ICC 0.831),检测颅内高压的AUC为0.786。

该前瞻性研究纳入18例入住ICU的成人卒中患者(蛛网膜下腔出血14例、脑出血3例、缺血性卒中1例),共60次同步测量,比较有创脑室内ICP监测与无创ICP波形监测(Brain4care)的波形形态参数(TTP和P2/P1比值)。P2/P1比值在分类(κ一致性88.1%)和连续(ICC 0.831)测量上均显示强一致性,TTP为中等一致性(κ 71.3%,ICC 0.584)。无创与有创方法均值ICP呈中等但显著相关(P2/P1比值 r=0.427;TTP r=0.353;p<0.001)。检测颅内高压的AUC:P2/P1比值0.786(95%CI 0.72-0.93),TTP 0.694(95%CI 0.60-0.74)。

要点

  • 在18例卒中患者60次测量中,无创ICP波形P2/P1比值与有创ICP的ICC为0.831,κ一致性88.1%。
  • TTP与有创ICP的一致性为中等:ICC 0.584,κ一致性71.3%。
  • 无创P2/P1比值检测颅内高压(有创ICP持续>20 mm Hg至少5 min)的AUC为0.786(95%CI 0.72-0.93)。
  • 无创TTP检测颅内高压的AUC为0.694(95%CI 0.60-0.74)。
  • 无创与有创方法均值ICP相关:P2/P1比值 r=0.427,TTP r=0.353,p<0.001。

适用人群与场景

  • 入住ICU的成人卒中患者,包括蛛网膜下腔出血、脑出血或缺血性卒中,且已放置有创ICP监测器。

诊断标准与关键阈值

  • 颅内高压定义为有创测量的ICP持续>20 mm Hg至少5 min。

研究设计与关键结果

  • 前瞻性研究,纳入18例患者(蛛网膜下腔出血14例、脑出血3例、缺血性卒中1例),共60次测量,中位年龄52±14.3岁。
  • 共分析197,400个波形(2495 min),切成1分钟段,从平均脉搏确定TTP和P2/P1比值。
  • 有创ICP中位数13(9.8-16.2)mm Hg,颅内高压出现于18次测量(30%)。
  • P2/P1比值分类一致性κ=88.1%,连续一致性ICC=0.831;TTP分类一致性κ=71.3%,连续一致性ICC=0.584。
  • 无创与有创均值ICP相关:P2/P1比值 r=0.427,TTP r=0.353,p<0.001。
  • 检测颅内高压AUC:P2/P1比值0.786(95%CI 0.72-0.93),TTP 0.694(95%CI 0.60-0.74)。

证据类型、等级与局限

  • 证据类型:前瞻性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,新型无创ICP波形监测器与标准有创方法一致性良好,检测颅内高压的判别力可接受。

指南或共识出处

  • 临床试验注册号:NCT05121155。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Although the placement of an intraventricular catheter remains the gold standard technique for measuring intracranial pressure (ICP), the method has several limitations. Therefore, noninvasive alternatives to ICP (ICPni) measurement are of great interest. The main objective of this study was to compare the correlation and agreement of wave morphology between ICP (standard intraventricular ICP monitoring) and a new ICPni monitor in patients admitted with stroke. The second objective was to estimate the discrimination of the noninvasive method to detect intracranial hypertension.

METHODS: We prospectively collected data of adults admitted to an intensive care unit with subarachnoid hemorrhage, intracerebral hemorrhage, or ischemic stroke in whom an invasive ICP monitor was placed. Measurements were simultaneously collected from two parameters [time-to-peak (TTP) and the ratio regarding the second and first peak of the ICP wave (P2/P1 ratio)] of ICP and ICPni wave morphology monitors (Brain4care). Intracranial hypertension was defined as an invasively measured sustained ICP > 20 mm Hg for at least 5 min.

RESULTS: We studied 18 patients (subarachnoid hemorrhage = 14; intracerebral hemorrhage = 3; ischemic stroke = 1) on 60 occasions with a median age of 52 ± 14.3 years. A total of 197,400 waves (2495 min) from both ICP (standard ICP monitoring) and the ICPni monitor were sliced into 1-min-long segments, and we determined TTP and the P2/P1 ratio from the mean pulse. The median invasively measured ICP was 13 (9.8-16.2) mm Hg, and intracranial hypertension was present on 18 occasions (30%). The correlation and agreement between invasive and noninvasive methods for wave morphology were strong for the P2/P1 ratio and moderate for TTP using categoric (κ agreement 88.1% and 71.3%, respectively) and continuous (intraclass correlation coefficient 0.831 and 0.584, respectively) measures. There was a moderate but significant correlation with the mean ICP value (P2/P1 ratio r = 0.427; TTP r = 0.353; p < 0.001 for all) between noninvasive and invasive techniques. The areas under the curve to estimate intracranial hypertension were 0.786 [95% confidence interval (CI) 0.72-0.93] for the P2/P1 ratio and 0.694 (95% CI 0.60-0.74) for TTP.

CONCLUSIONS: The new ICPni wave morphology monitor showed a good agreement with the standard invasive method and an acceptable discriminatory power to detect intracranial hypertension. Clinical trial registration Trial registration: NCT05121155.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. de Moraes FM, Rocha E, Barros FCD, et al. Waveform Morphology as a Surrogate for ICP Monitoring: A Comparison Between an Invasive and a Noninvasive Method. Neurocrit Care. 2022. PMID: 35332426. doi:10.1007/s12028-022-01477-4

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。